European Surveillance of Antimicrobial Consumption (ESAC): outpatient antibiotic use in Europe

Ferech, Matus; Coenen, Samuel; Malhotra-Kumar, Surbhi; Dvořáková, Kateřina; Hendrickx, Erik; Suetens, Carl; Goossens, Herman

doi:10.1093/jac/dkl188

Cited by 346 publications

(182 citation statements)

References 13 publications

Supporting

Mentioning

164

Contrasting

Unclassified

Order By: Relevance

“…[2] Ceftriaxone is a broad-spectrum cephalosporin antibiotic for IV or IM administration. Ceftriaxone was completely absorbed following IM administration with mean maximum plasma concentrations occurring between 2 and 3 h post-dose.…”

Section: Discussionmentioning

confidence: 99%

Ceftriaxone-Induced Fatal Anaphylaxis Shock at an Emergency Department: A Case Report

Imam¹,

Ibrahim²

2017

JPPCM

View full text Add to dashboard Cite

Anaphylaxis in adults caused by medications such as antibiotics are quite common. To best of our knowledge, the case of anaphylaxis caused by ceftriaxone in our hospital and clinical practice is rare and especially among Saudi patients. A 31-years old Arab female patient was admitted to the emergency (ER) department due to influenza symptoms. Patient was suspected having pneumonia after examination. History indicated that she did not have penicillin allergy in the past, no history of any other concomitant medications, and no other comorbidities. Patient was febrile. At ER department, she was given ceftriaxone 1 g intravenous (IV) and within 15 min the patient started to complain from shortness of breath, bronchospasm and developed irregularity of the vital signs. Patient was suspected experiencing anaphylactic shock. Ceftriaxone was discontinued. Aggressive management started immediately; patient was given oxygen, IM adrenaline, IV hydrocortisone, IV bolus of normal saline, IV ringer lactate, IV pheniramine, and IV ranitidine. Tepid water sponging was provided to control the fever. After resuscitative treatment, patient was stabilized and the vital signs were good. The patient then was moved out to the medical ward. Health care professionals at the Emergency Department should be mindful of the anaphylaxis possibility with patient receiving antibiotics in the cephalosporin group.

show abstract

Section: Discussionmentioning

confidence: 99%

Ceftriaxone-Induced Fatal Anaphylaxis Shock at an Emergency Department: A Case Report

Imam¹,

Ibrahim²

2017

JPPCM

View full text Add to dashboard Cite

show abstract

“…In addition, important variation in access to medicines exists between European countries, in particular between Western and Eastern countries. This is due to differences in marketing of medicines and their inclusion in national reimbursement lists, country's gross domestic product, government expenditure on health, and also due to medicine prices and utilization (for further information on differences between countries related to availability [11][12][13][14], prices [5,[15][16][17][18][19][20][21][22] and utilization [23][24][25][26][27][28][29][30] of medicines see A1 in the Supplementary Materials).…”

Section: Introductionmentioning

confidence: 99%

How Can Pricing and Reimbursement Policies Improve Affordable Access to Medicines? Lessons Learned from European Countries

Vogler

Paris

Ferrario

et al. 2017

Appl Health Econ Health Policy

135

118

View full text Add to dashboard Cite

Key points for Decision Makers: European countries apply different pharmaceutical pricing and reimbursement policies. These policies are frequently assessed against their financial consequences and their ability to contain costs but less so in terms of access to medicines. Policies should be accompanied by regular evaluations, facilitated by the use of the appropriate methodology and access to the relevant data. There appears to be a need for additional changes beyond traditional pharmaceutical pricing and reimbursement policies. Collaborative approaches (e.g. between countries or between regulatory authorities, pricing and reimbursement agencies) and more transparency in terms of real medicine prices, R+D costs and medicines in the pipeline are considered as possible pathways for the future. AbstractThe paper discusses pharmaceutical pricing and reimbursement policies in European countries with regard to their ability to ensure affordable access to medicines. A frequently applied pricing policy is external price referencing. While it provides some benchmark for policy-makers and has shown to be able to generate savings, it may also contribute to delay in product launch in countries where medicine prices are low. Value-based pricing has been proposed as a policy that promotes access while rewarding useful innovation, however implementing it has proven quite challenging. For high-priced medicines, managed-entry agreements are increasingly used. These agreements allow policy-makers to manage uncertainty and obtain lower prices. They can also facilitate earlier market access in case of limited evidence about added therapeutic value of the medicine. However, these agreements raise transparency concerns due to the confidentiality clause. Tendering as used in the 2 hospital and offpatent outpatient sectors has proven to reduce medicine prices but it requires a robust framework and appropriate design with clear strategic goals in order to prevent shortages. These pricing and reimbursement policies are supplemented by the widespread use of Health Technology Assessment to inform decision-making, and by strategies to improve the uptake of generics, and also biosimilars. While European countries have been implementing a set of policy options, there is a lack of thorough impact assessments of several pricing and reimbursement policies on affordable access. Increased cooperation between authorities, experience sharing, and improving transparency on price information, including the disclosure of confidential discounts, are opportunities to address current challenges.3

show abstract

“…Esta se emplea en diagnósticos como la otitis [10,11], sinusitis [10], amigdalitis [10], infecciones del tracto respiratorio [11], infecciones de la piel y tejidos blandos [11], entre otros. Según varios estudios, la amoxicilina y las penicilinas de amplio espectro son el antibiótico y el subgrupo farmacológico más consumido a nivel comunitario, en Colombia [7,[12][13][14], en América Latina [15] y en distintos países del mundo [16][17][18][19][20][21][22]. Su uso tan amplio ha llevado a sugerir que sea como efecto placebo en lugar del tratamiento específico en infecciones bacterianas [21].…”

Section: Introductionunclassified

Cualificación y experiencia de los vendedores de droguería para la dispensación de amoxicilina en una comuna de Santiago de Cali, Colombia

Espinosa

Molineros

2018

Rev. colomb. cienc. quim. farm.

View full text Add to dashboard Cite

Introducción. Un estudio en la comuna 5 de Santiago de Cali, encontró que el antibiótico más automedicado era la amoxicilina y que esta se asociaba a que fuese el vendedor de droguería quien la recomendaba. El presente estudio tiene como objetivo identificar la cualificación y experiencia de los vendedores de droguería en la comuna 5 de Santiago de Cali sobre la dispensación de amoxicilina. Metodología.Estudio de corte transversal en el que se encuestó un vendedor por droguería. Se estableció la asociación de la formación y experiencia con preguntas sobre uso del antibiótico. Resultados y discusiones. En su mayoría, los encuestados eran auxiliares de farmacia (35%), tenían más de cinco años de experiencia (81%); afirman que susclientes pocas veces presentan la fórmula médica (58%) y que ellos recomiendan su uso (62%). La pregunta de mayor acierto fue la relacionada con las precauciones y la de menor acierto la del tiempo de tratamiento. El 71% de los que tienen más de cinco años de experiencia acertaron en la pregunta sobre los efectos adversos (OR = 10,p < 0,05). Conclusiones. Entre menor es el nivel de formación, más frecuentemente recomiendan el uso del antibiótico, y todos los que no tenían formación en farmacia lo recomiendan.

show abstract

European Surveillance of Antimicrobial Consumption (ESAC): outpatient antibiotic use in Europe

Cited by 346 publications

References 13 publications

Ceftriaxone-Induced Fatal Anaphylaxis Shock at an Emergency Department: A Case Report

Ceftriaxone-Induced Fatal Anaphylaxis Shock at an Emergency Department: A Case Report

How Can Pricing and Reimbursement Policies Improve Affordable Access to Medicines? Lessons Learned from European Countries

Cualificación y experiencia de los vendedores de droguería para la dispensación de amoxicilina en una comuna de Santiago de Cali, Colombia

Contact Info

Product

Resources

About